Ondine

Ondine Biomedical Inc develops and markets topical, non-antibiotic treatments for infectious disease using photodynamic therapy as a platform technology. The Company is seeking to market a treatment for oral infectious disease.In September 2010, the company announced it was to change its name from Ondine Biopharma to Ondine Biomedical. The change was subject to approval from the Toronto Stock Exchange. In October 2010, the company changed its name, following approval from the Toronto Stock Exchange.By February 2003, Ondine had offices and research operations in Seattle, WA, and in Cincinnati, OH. At that time, the Company was engaged in completing a round of private seed investment, and was initiating a $5 million series-A fundraising from venture capital sources. In April 2007, Ondine's wholly owned research subsidiary was to relocate to new Bothell, Washington offices. Ondine was to close its office in York, Pennsylvania. The company's sales and marketing functions were to b